HuR’s post-transcriptional regulation of death receptor 5 in pancreatic cancer cells

References

• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY 2008;321(5897):1801-6.
   Google Scholar
• López de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, et al. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003; 22:7146 - 54; http://dx.doi.org/10.1038/sj.onc.1206862; PMID: 14562043
   PubMed Web of Science ®Google Scholar
• López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2:11 - 3; http://dx.doi.org/10.4161/rna.2.1.1552; PMID: 17132932
   PubMedGoogle Scholar
• Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Current opinion in cell biology.
   Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155 - 62; http://dx.doi.org/10.1172/JCI6926; PMID: 10411544
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157 - 63; http://dx.doi.org/10.1038/5517; PMID: 9930862
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9:2582 - 92; http://dx.doi.org/10.1158/1535-7163.MCT-10-0370; PMID: 20660600
   PubMed Web of Science ®Google Scholar
• Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201:331 - 40; http://dx.doi.org/10.1002/jcp.20099; PMID: 15389537
   PubMed Web of Science ®Google Scholar
• Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 2001; 20:399 - 403; http://dx.doi.org/10.1038/sj.onc.1204103; PMID: 11313970
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (New York, NY 1997;277(5327):815-8.
   Google Scholar
• Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17:2215 - 23; http://dx.doi.org/10.1093/emboj/17.8.2215; PMID: 9545235
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Oldenhuis CN, Szegezdi E, et al. Targeting Trail Towards the Clinic. Current drug targets.
   Google Scholar
• Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell cycle (Georgetown, Tex 2007;6(11):1288-92.
   Google Scholar
• Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65:3168 - 81; http://dx.doi.org/10.1007/s00018-008-8252-6; PMID: 18581050
   PubMed Web of Science ®Google Scholar
• Meng Z, King PH, Nabors LB, Jackson NL, Chen CY, Emanuel PD, et al. The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 2005; 33:2962 - 79; http://dx.doi.org/10.1093/nar/gki603; PMID: 15914670
   PubMed Web of Science ®Google Scholar
• Kullmann M, Göpfert U, Siewe B, Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5’UTR. Genes Dev 2002; 16:3087 - 99; http://dx.doi.org/10.1101/gad.248902; PMID: 12464637
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley interdisciplinary reviews;1(2):214-29.
   Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403 - 13; PMID: 9196156
   PubMed Web of Science ®Google Scholar
• Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69:4567 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-09-0371; PMID: 19487279
   PubMed Web of Science ®Google Scholar
• Richards NG, Rittenhouse DW, Freydin B, et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Annals of surgery 2010;252(3):499-505; discussion -6.
   Google Scholar
• Wang PY, Rao JN, Zou T, Liu L, Xiao L, Yu TX, et al. Post-transcriptional regulation of MEK-1 by polyamines through the RNA-binding protein HuR modulating intestinal epithelial apoptosis. Biochem J 2010; 426:293 - 306; http://dx.doi.org/10.1042/BJ20091459; PMID: 20001965
   PubMed Web of Science ®Google Scholar
• Durie D, Lewis SM, Liwak U, Kisilewicz M, Gorospe M, Holcik M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene 2011; 30:1460 - 9; http://dx.doi.org/10.1038/onc.2010.527; PMID: 21102524
   PubMed Web of Science ®Google Scholar
• Mazroui R, Di Marco S, Clair E, von Roretz C, Tenenbaum SA, Keene JD, et al. Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. J Cell Biol 2008; 180:113 - 27; http://dx.doi.org/10.1083/jcb.200709030; PMID: 18180367
   PubMed Web of Science ®Google Scholar
• Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, et al. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007; 7:108; http://dx.doi.org/10.1186/1471-2407-7-108; PMID: 17592646
   PubMed Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754 - 60; http://dx.doi.org/10.1093/bioinformatics/btp324; PMID: 19451168
   PubMed Web of Science ®Google Scholar
• Brody JR, Gonye, G.E. HuR’s Role in Gemcitabine Efficacy: An exception or opportunity? WIREs RNA 2010.
   Google Scholar
• Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000; 20:760 - 9; http://dx.doi.org/10.1128/MCB.20.3.760-769.2000; PMID: 10629032
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol Cancer Ther 2008; 7:1091 - 100; http://dx.doi.org/10.1158/1535-7163.MCT-07-2368; PMID: 18483298
   PubMed Web of Science ®Google Scholar
• Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, et al. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008; 27:6151 - 63; http://dx.doi.org/10.1038/onc.2008.215; PMID: 18641687
   PubMed Web of Science ®Google Scholar
• Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417 - 23; http://dx.doi.org/10.1074/jbc.273.11.6417; PMID: 9497373
   PubMed Web of Science ®Google Scholar
• von Roretz C, Gallouzi IE. Protein kinase RNA/FADD/caspase-8 pathway mediates the proapoptotic activity of the RNA-binding protein human antigen R (HuR). J Biol Chem 2010; 285:16806 - 13; http://dx.doi.org/10.1074/jbc.M109.087320; PMID: 20353946
   PubMed Web of Science ®Google Scholar
• von Roretz C, Macri AM, Gallouzi IE. Transportin 2 regulates apoptosis through the RNA-binding protein HuR. J Biol Chem 2011; 286:25983 - 91; http://dx.doi.org/10.1074/jbc.M110.216184; PMID: 21646354
   PubMed Web of Science ®Google Scholar